AmerisourceBergen makes available, free of charge via its website, all
Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current
Reports on Form 8-K and other information filed with or furnished to the
SEC, including amendments to such reports. This information is available
under the investors section at www.amerisourcebergen.com
as soon as reasonably practicable after it is electronically filed with
the SEC. In addition, all reports and information that AmerisourceBergen
files with or furnishes electronically to the SEC is available under the
Filings & Forms (EDGAR) section at www.sec.gov.
Alternatively, stockholders may receive a hard copy of the Annual Report
on Form 10-K, free of charge upon request. A written request should be
sent to Stockholder Relations, AmerisourceBergen Corporation, P.O. Box
959, Valley Forge, PA 19482.
About AmerisourceBergen
AmerisourceBergen is one of the world's largest pharmaceutical services
companies serving the United States, Canada and selected global markets.
Servicing both pharmaceutical manufacturers and healthcare providers in
the pharmaceutical supply channel, the Company provides drug
distribution and related services designed to reduce costs and improve
patient outcomes. AmerisourceBergen's service solutions range from
pharmacy automation and pharmaceutical packaging to reimbursement and
pharmaceutical consulting services. With more than $70 billion in annual
revenue, AmerisourceBergen is headquartered in Valley Forge, PA, and
employs approximately 11,000 people. AmerisourceBergen is ranked #28 on
the Fortune 500 list. For more information, go to www.amerisourcebergen.com.
Forward-Looking Statements
This news release may contain forward-looking statements about
AmerisourceBergen's future business and financial performance, estimates
and prospects. These statements are based on our current expectations
and are subject to uncertainty and change in circumstances. Among the
factors that could cause actual results to differ materially from those
projected, anticipated or implied are the following: changes in
pharmaceutical market growth rates; the loss of one or more key customer
or supplier relationships; changes in customer mix; customer or supplier
defaults or insolvencies; changes in pharmaceutical manufacturers'
pricing and distribution policies or practices; adverse resolution of
any contract or other dispute with customers or suppliers; federal and
state government enforcement initiatives to detect and prevent
suspicious orders of controlled substances and the diversion of
controlled substances; changes in U.S. legislation or regulatory action
affecting pharmaceutical product pricing or reimbursement policies,
including under Medicaid and Medicare; changes in regulatory or clinical
medical guidelines and/or labeling for the pharmaceuticals we
distribute, including erythropoiesis-stimulating agents (ESAs) used to
treat anemia patients; price inflation in branded pharmaceuticals and
price deflation in generics; significant breakdown or interruption of
our information technology systems; success of integration,
restructuring or systems initiatives; interest rate and foreign currency
exchange rate fluctuations; economic, business, competitive and/or
regulatory developments in Canada, the United Kingdom and elsewhere
outside of the United States; the impact of divestitures or the
acquisition of businesses that do not perform as we expect or that are
difficult for us to integrate or control; our inability to successfully
complete any other transaction that we may wish to pursue from time to
time; changes in tax legislation or adverse resolution of challenges to
our tax positions; our ability to maintain adequate liquidity and
financing sources; continued volatility and further deterioration of the
capital and credit markets; and other economic, business, competitive,
legal, tax, regulatory and/or operational factors affecting our business
generally. Our most recent annual report on Form 10-K, quarterly reports
on Forms 10-Q and current reports 8-K (which we may revise or supplement
in future reports filed to the SEC) provide additional information about
these risks, uncertainties and other matters. We do not undertake to
update our forward-looking statements.
SOURCE: AmerisourceBergen Corporation
AmerisourceBergen Corporation
Michael N. Kilpatric, 610-727-7118
mkilpatric@amerisourcebergen.com